VA testing GLP-1 drug for alcohol use disorder in vets

The Department of Veterans Affairs has launched a clinical trial to test whether semaglutide, a GLP-1 medication currently approved for diabetes and weight management, can help veterans struggling with alcohol use disorder. The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial, will enroll more than 600 veterans at 18 VA medical centers nationwide and represents the VA's effort to explore emerging treatment options for a condition that affects thousands of veterans.

Alcohol use disorder remains a significant health challenge within the veteran community, often linked to service-related trauma, chronic pain, and the stress of military life. The VA currently offers evidence-based treatments including counseling, medication-assisted therapy, and residential programs, but researchers are investigating whether GLP-1 medications might offer an additional tool by affecting parts of the brain involved in reward pathways. Semaglutide is not currently FDA-approved for treating alcohol use disorder, which is why this controlled trial is necessary to determine both safety and effectiveness.

The trial is open to veterans ages 18 to 80 who have been diagnosed with moderate or severe alcohol use disorder. Participants will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety evaluation period. Researchers will track changes in alcohol consumption, overall health outcomes, and quality of life throughout the study period.

Recruitment for the CRAVE trial began on July 28. Veterans interested in participating can contact their local VA medical center or search for the trial on ClinicalTrials.gov to find participating locations and determine if they meet eligibility criteria. The VA has emphasized that veterans should not attempt to self-medicate with GLP-1 medications or replace their current evidence-based alcohol use disorder treatments without consulting a healthcare provider first.

The trial builds on research from Washington University School of Medicine and other institutions that have studied GLP-1 medications for substance use disorders. An analysis published in March found that patients taking GLP-1 medications experienced lower rates of alcohol use disorder and other substance use disorders compared to similar patients taking other diabetes medications, though the VA noted that larger controlled trials are needed to confirm these findings. VA Secretary Doug Collins stated that "by exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery."

For disabled veterans, this trial matters because alcohol use disorder often intersects with service-connected disabilities, particularly mental health conditions like PTSD and depression. Effective treatment for substance use disorders can improve overall health outcomes, potentially affecting disability ratings and quality of life. The trial also reflects the VA's broader commitment to researching innovative treatments specifically tailored to veteran populations rather than simply adopting civilian medical protocols.

Veterans currently receiving treatment for alcohol use disorder should continue with their existing care plans and discuss this trial with their VA provider if interested in participating. Those not currently in treatment but struggling with alcohol use should reach out to their VA medical center to explore all available treatment options, whether through this trial or established programs. The VA's mental health and substance use services are available regardless of disability rating or service connection status for enrolled veterans.